News

Sunovion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA), clearing the Massachusetts company from having to conduct further clinical trials for approval of its SUN-101/eFlow (glycopyrrolate) therapy to treat chronic obstructive pulmonary disease (COPD). According to a corporate press release, the CRL clears Sunovion…

Dutch healthcare conglomerate Royal Philips has purchased RespirTech, a leading manufacturer of airway clearance therapy vests for patients with chronic obstructive pulmonary disease (COPD) and other severe lung conditions. With this new acquisition, Philips expands its respiratory care portfolio, strengthening its presence in the hospital and home care markets —  especially…

A recent study, co-sponsored by Royal Philips, showed that using home noninvasive ventilation in addition to home oxygen therapy (HOT) could effectively delay hospital readmissions and increase survival in patients with advanced chronic obstructive pulmonary disease (COPD) after a life-threatening respiratory event or exacerbation. The study, “Effect of Home Noninvasive…

Using a ventilator to control the level of supplemental oxygen a chronic obstructive pulmonary disease (COPD) patient receives halved patients’ trips to the hospital from disease flare-ups, according to a clinical trial. Britishers researchers conducted the study, which they dubbed the Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) trial (…

Ndd Medical Technologies will showcase the latest versions of its best-in-class spirometer and portable, all-in-one DLCO (diffusing capacity for carbon monoxide) devices for lung conditions such as chronic obstructive pulmonary disease (COPD) and asthma at an upcoming conference in the nation’s capital. The annual American Thoracic Society (ATS 2017) Conference is…

Sunovion Pharmaceuticals will present data from Phase 3 studies of SUN-101/eFlow as a potential maintenance therapy for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society 2017 International Conference (ATS 2017), to be held May 19-24 in Washington, D.C. Sunovion will also present data on both Brovana…

Pulmatrix has received a key U.S. patent for its lead inhaled drug candidate PUR0200 to treat chronic obstructive pulmonary disease (COPD). The drug, still under development in the United States and Europe, is a long-acting muscarinic antagonist (LAMA) bronchodilator. Thanks to Pulmatrix’s iSPERSE technology, PUR0200 can reportedly achieve the same effect…

Plain tobacco packaging could reduce the appeal of smoking, decreasing the alarming rate of chronic obstructive pulmonary disease (COPD), according to the Cochrane Review. The article, “Tobacco packaging design for reducing tobacco use,” was published in Cochrane Library. Cochrane is a non-profit that organizes medical research information…

Patients with chronic obstructive pulmonary disease (COPD) who also have non-tuberculous mycobacterial pulmonary disease (NTM-PD) are more likely to be hospitalized and die, according to a German study that urges improved care for this particular disease. The study,“Burden of non-tuberculous mycobacterial pulmonary disease in Germany,” appeared in the European…

Treatment with a triple combo therapy in a single inhaler decreased exacerbation rates in COPD patients compared with tiotropium treatment, according to the results of a clinical trial. The triple combo is composed of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) — BDP/FF/GB. This combination has been shown…